EKF Diagnostics Holdings plc said it repurchased 60,000 of its ordinary shares at a weighted average price of 25 pence each via two transactions executed on the AIM exchange.
The buybacks occurred on a single trading day, with 50,000 shares acquired at 08:17:26 GMT and the remaining 10,000 shares purchased at 16:35:33 GMT, both at the same price of 25 pence per share. All repurchased shares will be cancelled, reducing the company’s total issued share capital.
Following the cancellation, EKF Diagnostics’ issued share capital will consist of 428,268,112 ordinary shares of 1 pence each, with no shares held in treasury. The move adjusts the total number of voting shares, which shareholders may use as the denominator for Disclosure Guidance and Transparency Rules notifications to the UK Financial Conduct Authority.
Headquartered in Penarth, Wales, EKF Diagnostics operates as a global diagnostics business specialising in point-of-care analysers for hematology and diabetes, alongside life sciences services. The company maintains five manufacturing sites across the United States and Germany and distributes products to more than 120 countries worldwide.
